China's pharmaceutical industry is entering its best era, and the environment for innovative drug development is improving. In addition to the continuous reform and optimization of regulatory policies and the numerous experts from all fields, capital investment has become an indispensable driving force for the accelerated development of the pharmaceutical industry. It is a great honor for Sciwind to obtain the recognition of many investment institutions for its management team, pipeline and R&D capability. These investment institutions provide effective financial support for the long-term development of the company.